Combined oxidative phosphorylation defect type 11
kuhm-bahyndd ahk-si-dey-tiv fos-for-uh-ley-shuhn dih-fekt tahyp ih-lev-uhn
Also known as: COXPD11, OXA1L-related mitochondrial disorder
At a Glance
What is Combined oxidative phosphorylation defect type 11?
Combined oxidative phosphorylation defect type 11 is a rare genetic disorder that affects the mitochondria, the energy-producing parts of cells. It primarily impacts the nervous system, leading to neurological symptoms. The condition is caused by mutations in the OXA1L gene, which disrupts mitochondrial function. Over time, affected individuals may experience worsening muscle weakness, developmental delays, and seizures. Early symptoms often include poor muscle tone and feeding difficulties, while later symptoms can involve more severe neurological impairments. Early diagnosis is crucial to manage symptoms and improve quality of life. The disorder can place a significant emotional and financial burden on families. Prognosis varies, but many affected individuals have a shortened lifespan. Daily life for those with the condition often involves ongoing medical care and support. The disorder can limit physical activities and require specialized educational plans. Despite these challenges, supportive therapies can help improve outcomes and quality of life.
Medical Definition
Combined oxidative phosphorylation defect type 11 is characterized by a defect in the mitochondrial respiratory chain, specifically involving complex assembly. Pathologically, it involves impaired ATP production due to dysfunctional oxidative phosphorylation. Histological findings may show ragged red fibers and abnormal mitochondrial morphology. The condition is classified under mitochondrial disorders and is associated with mutations in the OXA1L gene. Epidemiologically, it is extremely rare, with only a few cases reported worldwide. The disease course is progressive, often leading to severe neurological impairment and early mortality.
Combined oxidative phosphorylation defect type 11 Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Muscle weakness manifests as a reduced ability to exert force with the muscles, often leading to difficulty in performing everyday tasks. This symptom is caused by impaired energy production in muscle cells due to defective oxidative phosphorylation. Over time, muscle weakness can progress, leading to increased fatigue and decreased mobility. It affects daily life by limiting physical activities, but physical therapy and supportive care can help manage the condition.
Developmental delay is observed as a lag in reaching milestones such as walking, talking, or social interaction. It is caused by insufficient energy production in brain cells, affecting cognitive and motor development. As the child grows, the delay may become more pronounced, impacting educational and social opportunities. Early intervention with therapies can help improve developmental outcomes.
Seizures present as sudden, uncontrolled electrical disturbances in the brain, leading to changes in behavior, movements, or consciousness. They occur due to energy deficits in neuronal cells, which disrupt normal brain activity. Seizures can become more frequent or severe over time if not managed properly. Antiepileptic medications and regular monitoring can help control seizures and improve quality of life.
Common
Lactic acidosis is characterized by an accumulation of lactic acid in the body, leading to symptoms like rapid breathing, nausea, and abdominal pain. It results from the body's reliance on anaerobic metabolism due to impaired oxidative phosphorylation. If untreated, lactic acidosis can worsen and lead to severe complications. Management includes addressing the underlying mitochondrial dysfunction and supportive care to stabilize acid-base balance.
Failure to thrive is seen as inadequate growth or inability to gain weight, often observed in infants and young children. This occurs due to increased energy demands and inefficient energy production in cells. Without intervention, it can lead to malnutrition and developmental issues. Nutritional support and addressing the underlying metabolic defect are crucial for improving growth outcomes.
Hypotonia, or decreased muscle tone, is evident as floppy limbs and poor head control, especially in infants. It is caused by insufficient energy supply to muscle cells, affecting their ability to maintain tone. Over time, hypotonia can impact motor skills and posture. Physical therapy and supportive measures can help improve muscle tone and function.
Less Common
Cardiomyopathy presents as an abnormality in the heart muscle, leading to symptoms like fatigue, shortness of breath, and arrhythmias. It is caused by energy production defects in cardiac cells, affecting heart function. If left untreated, it can progress to heart failure. Management includes medications to support heart function and regular cardiac monitoring.
Hearing loss may manifest as difficulty in hearing sounds or understanding speech, often detected in early childhood. It occurs due to impaired energy production in the auditory cells of the inner ear. Over time, hearing loss can affect communication and language development. Hearing aids and auditory therapies can help improve hearing and communication skills.
What Causes Combined oxidative phosphorylation defect type 11?
Combined oxidative phosphorylation defect type 11 is primarily caused by mutations in the OXA1L gene, located on chromosome 14q11.2. The OXA1L gene encodes the OXA1L protein, which is integral to the inner mitochondrial membrane and plays a crucial role in the insertion and assembly of mitochondrial membrane proteins. Mutations in OXA1L can lead to structural alterations in the protein, impairing its ability to facilitate the proper assembly of the electron transport chain complexes. This disruption results in defective oxidative phosphorylation, leading to reduced ATP production and increased production of reactive oxygen species (ROS). The mitochondrial dysfunction triggers a cascade of cellular stress responses, including the activation of apoptotic pathways and impaired calcium homeostasis. As mitochondria are essential for energy production, their dysfunction particularly affects high-energy-demand tissues such as the brain and muscles. In the central nervous system, mitochondrial dysfunction can lead to neuroinflammation, characterized by the activation of microglia and astrocytes. This inflammatory response contributes to the degeneration of white matter and neuronal loss, exacerbating neurological symptoms. The specific pattern of symptoms, such as encephalopathy and muscle weakness, is due to the differential energy demands and mitochondrial dependency of various tissues. Variability in disease severity among patients can be attributed to the heterogeneity of mutations, differences in mitochondrial DNA background, and environmental factors. Additionally, the presence of modifier genes and the individual's capacity for mitochondrial biogenesis and repair may influence the clinical outcome. The progressive nature of the disease is often linked to the cumulative damage from oxidative stress and the inability of cells to compensate for the energy deficit. Understanding the precise molecular mechanisms and pathways affected by OXA1L mutations is crucial for developing targeted therapeutic strategies.
How is Combined oxidative phosphorylation defect type 11 Diagnosed?
Typical age of diagnosis: Combined oxidative phosphorylation defect type 11 is typically diagnosed in infancy or early childhood when symptoms such as developmental delay, muscle weakness, and neurological abnormalities become apparent. Diagnosis often follows a series of clinical evaluations and laboratory tests prompted by these early signs.
Clinicians look for signs of developmental delay, muscle weakness, and neurological abnormalities. A detailed family history is important to identify any hereditary patterns. Physical examination may reveal hypotonia and failure to thrive. This step helps to determine the need for further specialized testing.
Magnetic Resonance Imaging (MRI) of the brain is commonly used. It may show abnormalities such as brain atrophy or lesions in the basal ganglia. These findings support the diagnosis of a mitochondrial disorder and help exclude other neurological conditions. Imaging results guide the clinician towards specific genetic tests.
Blood and urine tests are ordered to measure lactate and pyruvate levels. Elevated levels of these biomarkers suggest a mitochondrial dysfunction. Abnormal results prompt further investigation into mitochondrial enzyme activities. Laboratory findings help prioritize genetic testing for specific mitochondrial genes.
The OXA1L gene is sequenced to identify pathogenic mutations. Mutations such as missense or nonsense changes confirm the diagnosis. Genetic results provide a definitive diagnosis and are crucial for family counseling. They also help assess the risk of recurrence in future pregnancies.
Combined oxidative phosphorylation defect type 11 Treatment Options
Coenzyme Q10 is an antioxidant that supports mitochondrial function. It works by improving electron transport chain efficiency. Clinical trials have shown some improvement in muscle strength and neurological function. However, efficacy varies and side effects may include gastrointestinal discomfort. Long-term benefits are still under investigation.
Techniques include stretching, strengthening, and motor skills exercises. The goal is to improve muscle tone and coordination. Sessions are typically conducted 2-3 times a week for 30-60 minutes. Outcomes are measured by improvements in motor milestones and functional abilities. Long-term benefits include enhanced quality of life and reduced disability.
Indicated for patients with severe feeding difficulties and failure to thrive. The procedure involves placing a tube directly into the stomach for nutritional support. Benefits include improved nutritional status and growth. Risks include infection and tube dislodgement. Post-operative care involves regular monitoring and tube maintenance.
The team includes neurologists, dietitians, physical therapists, and genetic counselors. Interventions focus on symptom management and nutritional support. Psychosocial support is provided through counseling and support groups. Family education is crucial for home care and emergency planning. Long-term monitoring involves regular follow-up visits and adjustment of care plans.
When to See a Doctor for Combined oxidative phosphorylation defect type 11
- Severe muscle weakness or paralysis — this can indicate a critical progression of the disease affecting respiratory muscles, requiring immediate medical intervention.
- Sudden loss of consciousness — could be a sign of a severe metabolic crisis or encephalopathy, necessitating emergency care.
- Persistent seizures — may indicate worsening neurological involvement, requiring urgent medical evaluation and treatment.
- Progressive fatigue — could signify worsening mitochondrial function; consult a healthcare provider for evaluation.
- Developmental delays in children — may indicate the condition is affecting neurological development; seek pediatric assessment.
- Unexplained weight loss — could suggest metabolic dysfunction; a medical evaluation is recommended.
- Mild muscle pain — monitor for changes in intensity or frequency and discuss with a doctor if it worsens.
- Occasional headaches — keep track of frequency and severity; consult a healthcare provider if they become more frequent or severe.
Combined oxidative phosphorylation defect type 11 — Frequently Asked Questions
Is this condition hereditary?
Combined oxidative phosphorylation defect type 11 is typically inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have mutations. Parents of an individual with this condition are usually carriers, meaning they have one mutated gene but do not show symptoms. De novo mutations, which are new mutations not inherited from either parent, are rare but possible. Carrier parents have a 25% chance of passing the condition to their children with each pregnancy. Genetic counseling is recommended for families to understand inheritance patterns and risks.
What is the life expectancy for someone with this condition?
Life expectancy can vary significantly depending on the age of onset and severity of symptoms. Early-onset cases often have a poorer prognosis due to rapid disease progression, while later-onset cases may have a more stable course. Mortality is often due to respiratory failure or severe metabolic crises. Treatment can improve quality of life and potentially extend survival, but outcomes depend on individual response. Families should discuss realistic expectations with their healthcare team.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves a combination of clinical evaluation, biochemical tests, and genetic testing. The time from first symptoms to diagnosis can vary, often taking months to years due to the rarity and complexity of the condition. Neurologists, geneticists, and metabolic specialists are typically involved in the diagnostic process. Delays often occur due to the overlap of symptoms with other more common conditions. Genetic testing confirming mutations in the OXA1L gene typically finalizes the diagnosis.
Are there any new treatments or clinical trials available?
Research is ongoing, with some promising studies focusing on gene therapy and mitochondrial-targeted treatments. Novel approaches such as enzyme replacement therapy are also being explored. ClinicalTrials.gov is a resource for finding current trials, and patients should discuss potential participation with their doctor. It's important to ask about the risks and benefits of experimental treatments. New treatments may still be several years away from being widely available.
How does this condition affect daily life and activities?
The condition can significantly impact mobility and self-care, often requiring assistive devices or personal care support. Educational accommodations may be necessary due to cognitive or physical challenges. Social and emotional challenges are common, affecting both the individual and their family. The condition can place a significant burden on families, necessitating support from healthcare providers and community resources. Adaptations such as physical therapy and counseling can help improve quality of life.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.OXA1L mutations cause mitochondrial encephalopathy and a combined oxidative phosphorylation defect.
Thompson K, Mai N, Oláhová M et al. · EMBO Mol Med · 2018 · PMID: 30201738
- 2.MitoQ alleviates carbon tetrachloride-induced liver fibrosis in mice through regulating JNK/YAP pathway.
Shan S, Liu Z, Liu Z et al. · Toxicol Res (Camb) · 2022 · PMID: 36337246
- 3.Oxidative phosphorylation-dependent regulation of cancer cell apoptosis in response to anticancer agents.
Yadav N, Kumar S, Marlowe T et al. · Cell Death Dis · 2015 · PMID: 26539916
- 4.Epigenetic changes related to glucose metabolism in type 1 diabetes after BCG vaccinations: A vital role for KDM2B.
Dias HF, Kühtreiber WM, Nelson KJ et al. · Vaccine · 2022 · PMID: 33933315
- 5.Cardiac manifestations in oxidative phosphorylation disorders of childhood.
Yaplito-Lee J, Weintraub R, Jamsen K et al. · J Pediatr · 2007 · PMID: 17382120
- 6.Mitochondrial GSH replenishment as a potential therapeutic approach for Niemann Pick type C disease.
Torres S, Matías N, Baulies A et al. · Redox Biol · 2017 · PMID: 27888692
- 7.Intratumoral heterogeneity of oxygen metabolism and neovascularization uncovers 2 survival-relevant subgroups of IDH1 wild-type glioblastoma.
Stadlbauer A, Zimmermann M, Doerfler A et al. · Neuro Oncol · 2018 · PMID: 29718366
- 8.Development of a human mitochondrial oligonucleotide microarray (h-MitoArray) and gene expression analysis of fibroblast cell lines from 13 patients with isolated F1Fo ATP synthase deficiency.
Cízková A, Stránecký V, Ivánek R et al. · BMC Genomics · 2008 · PMID: 18221507
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-06-15